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Summary The vital signs of pulse rate, blood pressure, temperature and respiratory rate
are the ‘nub’ of individual patient management. At the programmatic level, vital signs could
also be used to monitor the burden and treatment outcome of chronic disease. Case detection
and treatment outcome constitute the vital signs of tuberculosis control within the WHO’s
‘DOTS’ framework, and similar vital signs could be adapted and used for management of chronic
diseases. The numbers of new patients started on therapy in each month or quarter (new
incident cases) are sensitive indicators for programme performance and access to services.
Using similar reporting cycles, treatment outcomes for all patients can be assessed, the vital
signs being: alive and retained on therapy at the respective facility; died; stopped therapy;
lost to follow-up; and transferred out to another facility. Retention on treatment constitutes
the prevalent number of cases, the burden of disease, and this provides important strategic
information for rational drug forecasting and logistic planning. If case numbers and outcomes of
chronic diseases were measured reliably and consistently as part of an integrated programmatic
approach, this would strengthen the ability of resource-poor countries to monitor and assess
their response to these growing epidemics.
© 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.
∗ Corresponding author. Present address: Old Inn Cottage, Vears
Lane, Colden Common, Winchester SO21 1TQ, UK.
Fax: +44 1962 714 297.
E-mail address: adharries@theunion.org (A.D. Harries).
1. Vital signs in clinical medicine
As every clinician and nurse knows, the measurement,
recording and reporting of clinical vital signs is an integral
part of individual patient management. These vital signs
are pulse rate, blood pressure, temperature and respiratory
rate. Healthy adults have a similar range of baseline vital
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signs that allows for individual variation. These signs change
in illness and, to the experienced health worker, provide an
immediate sense of underlying pathology. For example, a
high fever, fast pulse rate and low blood pressure indicate
possible septic shock, whilst a slow pulse rate and high blood
pressure indicate possible raised intracranial pressure. Once
a diagnosis is made and treatment instituted, the vital signs
are monitored on patient treatment cards and regularly
entered into progress charts and patient case ﬁles. Provided
they are correctly measured and adequately recorded, they
serve as a crucial tool to determine response to therapy.
In well resourced countries, monitoring of vital signs
may be supplemented with more sophisticated monitoring
of central venous pressure, pulmonary wedge pressure and
so on, but in any setting the basic vital signs remain the
‘nub’ of clinical management.
2. Programmatic management of chronic
disease in resource-poor settings
The prevalence and incidence of non-communicable
diseases such as hypertension, diabetes mellitus, cardio-
vascular disease, obstructive airways disease and asthma
grow inexorably each year and increasingly affect patients
and communities in resource-poor settings.1 For example,
in 2007 diabetes mellitus was estimated to affect 246 mil-
lion people globally, with 6 million new cases and 3.5 million
deaths: 70% of this burden was in developing countries, par-
ticularly in Southeast Asia and the Western Paciﬁc.2 Similar
numbers pertain to asthma: 300 million patients estimated
to be living with the disease and 250000 deaths annually,
with the majority in developing countries.3 These patients
usually need chronic, life-time care and treatment, but in
most resource-poor countries, outside of a few centres of
excellence, this is simply not provided and there are no
systems to monitor patient numbers or outcomes.
3. Vital signs of chronic disease management
Based on pioneering work by the International Union against
Tuberculosis and Lung Disease, the ‘DOTS’ framework for
tuberculosis (TB) control was developed by the WHO to
expand, deliver and monitor TB treatment to millions of
patients throughout the world.4 Case detection and treat-
ment outcome constitute the vital signs of TB control within
this framework. Since the initiation of DOTS programmes in
1995, remarkable progress has been made and, through a
simple recording and reporting system on case numbers and
treatment outcomes, progress towards meeting case detec-
tion and treatment success targets have been monitored
annually at national and global levels.5
In a previous publication, we have described how the
DOTS paradigm could be adapted for the management of
non-communicable diseases, focusing on political commit-
ment, case ﬁnding, standardised treatment, standardised
monitoring, evaluation and drug quantiﬁcation.6 We have
also explained how this model could be implemented and
scaled up in a phased approach at the country level. Since
then, we have further developed our thoughts on the moni-
toring component of this model. In this current paper, we put
forward what we believe are the vital signs of chronic infec-
tious and non-infectious disease management and explain in
detail the rationale and interpretation of these signs. The
vital signs comprise case numbers and treatment outcomes,
which, if measured reliably and consistently in all patients
and as an integral part of a programmatic approach, would
enormously strengthen the ability of resource-poor coun-
tries to monitor and assess their response to the growing
epidemics of chronic diseases.
The number of registered cases can be subdivided into
the number of new patients started on therapy in each
quarter of a year (new incident cases) and the cumulative
number ever started on therapy. The number of new regis-
trations is one of the ‘vital signs’ and is a sensitive indicator
for programme performance. If estimates for disease inci-
dence are available, the number of new registrations can be
used to monitor access to services. Using the same quarterly
reporting cycle, treatment outcomes for all patients ever
registered can be assessed, with the vital signs being: alive
and retained on therapy at the respective facility; died;
stopped therapy; lost to follow-up; and formally transferred
out to another facility. Those alive and on treatment can
be subdivided, according to type of disease, into those who
have improved, remained stable or become worse: such a
system has been used for patients with asthma.7 For the
ascertainment of retention in care, chronologically com-
pleted treatment cards or electronic patient data systems
are needed that are updated at every follow-up visit. To
interpret the vital signs correctly, treatment outcomes must
be clearly deﬁned and applied consistently.
Death may be ascertained proactively by a relative or
friend providing information to the personnel at the clinic,
or it may be discovered by the clinic team as part of active
tracing of patients who failed to attend their appointment.
Similarly, patients who have stopped therapy may inform
the clinic, but it is more likely that this information will
be discovered through active tracing. Thus, the deﬁnition
of lost to follow-up and the management of these patients
becomes a crucial programmatic activity. In antiretroviral
therapy (ART) clinics in Malawi, defaulters are classiﬁed as
patients failing to attend the clinic for ≥3 months.8 In an
operational research study to determine the true outcomes
of these patients, 50% had died, 15% had stopped therapy
and 8% had transferred to another clinic and failed to inform
their original clinic of this move.8 An outcome of lost to
follow-up can thus change as accurate information becomes
available about the true status of the patient. Similarly, an
outcome of stopped treatment can change if the patient is
persuaded to return to therapy.
4. Interpretation of vital signs
The adverse outcomes of death, lost to follow-up and
stopped treatment are a gauge for clinic and programme
performance as they indicate ‘attrition’ from care. High
death rates show poor effectiveness of therapy and can be
related to limitations of access and to late presentation
for diagnosis and treatment. High rates of loss to follow-
up indicate low levels of active tracing by the clinic. High
numbers of patients stopping therapy indicate insufﬁcient
patient education about the disease, the necessity of con-
tinued treatment or side effects.Author's personal copy
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Patients transfer out from one clinic to another for
personal, family and occupational reasons. There is little
documented data on what happens to patients who trans-
fer out in chronic care situations, although in Malawi the
majority of patients on ART who formally transferred out in
fact transferred in to another facility.9 Transfer out is not an
adverse outcome but, if not taken into account, can lead to
double counting of patients at the national level.
The number of patients alive and on treatment is a vital
piece of strategic information. This is the prevalent num-
ber of cases and the current burden of disease. If measured
regularly and accurately this information is important in its
own right, but it also provides the necessary data for rational
drug forecasting and planning of logistics and stafﬁng.
5. Supplementing the vital signs
Depending on the human resource base and the sophistica-
tion of the clinic, other indicators or signs can be added
that may be help to understand better the case burden,
gauge the response to treatment and work out drug and
commodity supplies. Stratiﬁcation by males and females and
by age allows more in-depth epidemiological assessment of
case burden and more precise forecasting of quantities of
adult and paediatric drug formulations. Knowledge of types
of medication for new incident and prevalent cases, for
example oral hypoglycaemic drugs and short-, medium- and
long-acting insulin preparations for patients with diabetes
mellitus, provide a ﬁrm platform for rational forecasting
and procurement, two activities that should prevent the fre-
quent stock interruptions that plague the developing world.
In patients with diabetes mellitus, regular recording of blood
glucose or glycosylated haemoglobin concentrations would
provide an objective measure of diabetes control quality,
and regular recording of eye, vascular, neurological and
renal complications would provide a measure of morbidity.
Regular reviews of structured patient treatment cards also
allow objective judgements about how well health workers
adhere to standard case management practices, including
complete diagnostic evaluation, correct classiﬁcation and
appropriate therapy.
6. Recording and reporting on vital signs
As with vital sign recording in individual patients, the date of
an adverse outcome or a transfer-out needs to be recorded
on the treatment card and patient register. The treatment
card and the register are the two important tools for mon-
itoring vital signs of chronic diseases, and how these might
look and function at the clinic level have already been
described.6 Treatment cards provide the complete chrono-
logical follow-up history for each patient, whilst registers
provide an up-to-date summary at any moment in time of
the current outcome status of all registered patients, pro-
vided of course that data in treatment cards are regularly
updated to the registers.
The treatment cards and register are then used to (a) pro-
vide cumulative outcome data at set periods of time for the
whole cohort of patients ever registered for treatment and
(b) survival outcome data in speciﬁed cohorts.6 As succes-
sive registration cohorts appear in chronological sequence in
the register, quarterly outcome analysis can easily be per-
formed for different lengths of follow-up (i.e. 12 months, 24
months, 36 months and so on), thereby allowing facilities
to produce and review comparable survival analyses that
are standardised for the length of observation. This exer-
cise can be done manually, but as the numbers grow it is
better handled through electronic data systems. For exam-
ple, using open-source software, EpiData, electronic patient
records have been prepared for the management and mon-
itoring of patients with asthma. Such data can be collected
and collated at district, provincial and national levels.
7. Linkage with general health systems
The initial DOTS framework,4 developed and disseminated
in 1994, has subsequently been modiﬁed and enhanced to
takeaccountofexperiencegainedoverthepreviousdecade,
critical problems such as HIV and drug resistance, and the
changing global architecture of healthcare delivery that has
seen a greater emphasis on health system strengthening
rather than disease-speciﬁc approaches. For example, it
became apparent 10 years ago that the DOTS framework
on its own would not be sufﬁcient to control TB in areas
with epidemic HIV infection.10 As a result, an interim pol-
icy was developed to deﬁne collaborative activities that
could reduce the dual burden of HIV and TB,11 and this
was then integrated into the new Global Plan to Stop TB
(2006—2015)12 and the new Stop TB Strategy.13 TB control
efforts now take account of HIV and multidrug-resistant TB,
and they have also been positioned within a framework that
seeks to reduce poverty, advance development and align
with other strategies to meet all public health challenges. In
this regard, there are new key components that (a) address
how TB control can contribute to strengthening of health
systems, (b) provide for greater engagement of all care
providers both from public and private sectors and (c) seek
to empower people with TB and the communities in which
they live.
In a similar vein, the setting up of a monitoring system
that seeks regularly to document incident and prevalent
cases, treatment outcomes and types of medication used by
patients with chronic infectious and non-infectious diseases
must be sensitive to the needs of general health systems,
otherwise there is a risk of setting up multiple parallel or
‘vertical’ programmes. This being said, many urban hospi-
tals in developing countries already run special clinics for
patients with diabetes mellitus, hypertension or asthma,
but consideration could be given to merging these into sin-
gle clinics for chronic diseases as has happened in hospitals
and health centres in Cambodia14 and Ethiopia.15 In health
facilities without these special clinics, patients with chronic
diseases may not efﬁciently access the services they need:
this has been our experience with asthma patients who,
when there are no asthma clinics available, access care
through unplanned visits, which leads to increased costs
and generally poor quality management. For all clinics serv-
ing special populations, regular, structured supervision will
be needed to ensure that monitoring systems are of good
quality, but these supervisory activities can be developed
and expanded for the wider health sector as well as for
chronic diseases. There is a growing conviction that so-Author's personal copy
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called ‘vertical programmes’ can be used and adapted to
drive broad improvements throughout the general health
system, particularly in hitherto weak areas such as mon-
itoring, supervision, quality assurance and rational drug
forecasting.16 Any attempt to improve the management and
monitoring of special diseases must include a vision of how
this will ultimately improve the health sector and healthcare
delivery as a whole.
8. Conclusion
With TB DOTS expansion and the scaling up of ART in some
of the poorest countries of the world, much has been learnt
about how to monitor case registration, patient burden and
treatment outcome, and these have become the vital signs
used to manage and evaluate these two treatment pro-
grammes. AIDS patients take ART for life in much the same
way as diabetic patients take insulin, hypertensive patients
take blood pressure medication and epileptic patients take
phenytoin. The same vital signs can be adapted to monitor
any chronic disease and should become the ‘nub’ of chronic
disease management.
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